The Pivotal Role of FDG-PET/CT in Modern Medicine

Academic Radiology

Volumn 21, Issue 2, 2014, Pages 232-249

  Hess, Søren ^a   Blomberg, Björn A ^a,b   Zhu, Hongyun June ^c   Høilund Carlsen, Poul Flemming ^a   Alavi, Abass ^d  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

2 deoxy 2 18F fluoro D glucose; FDG; Molecular imaging; PET CT; Positron emission tomography computed tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ALZHEIMER DISEASE; AORTA ARCH SYNDROME; ATHEROSCLEROSIS; BONE INFECTION; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC OSTEOMYELITIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; GIANT CELL ARTERITIS; GLIOMA; HUMAN; MOLECULAR IMAGING; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PARANEOPLASTIC SYNDROME; PARKINSON DISEASE; PATIENT CARE; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; RHEUMATIC POLYMYALGIA; SENSITIVITY AND SPECIFICITY; SOFT TISSUE INFECTION; TECHNOLOGY; WHOLE BODY CT; WHOLE BODY IMAGING;

2-DEOXY-2-[18F]FLUORO-D-GLUCOSE; FDG; MOLECULAR IMAGING; PET/CT; POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY;

FLUORODEOXYGLUCOSE F18; HUMANS; MOLECULAR IMAGING; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84892470981     PISSN: 10766332     EISSN: 18784046     Source Type: Journal    
DOI: 10.1016/j.acra.2013.11.002     Document Type: Review

References (157)

1. Alavi A., Reivich M. The conception of FDG-PET imaging. Semin Nucl Med 2002, 32:2-5.
2. 18F-labeled positron emission tomographic radiopharmaceuticals in oncology: An overview of radiochemistry and mechanisms of tumor localization. Semin Nucl Med 2007, 37:400-419.
3. Warburg O. On the origin of cancer cells. The metabolism of tumors 1931, 129-169. Richard R. Smith, New York.
4. Macheda M.L., Rogers S., Best J.D. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005, 202:654-662.
5. Medina R.A., Owen G.I. Glucose transporters: expression, regulation and cancer. Biol Res 2002, 35:9-26.
6. Basu S., Kung J., Houseni M., et al. Temporal profile of fluorodeoxyglucose uptake in malignant lesions and normal organs over extended time periods in patients with lung carcinoma: implications for its utilization in assessing malignant lesions. Q J Nucl Med Mol Imaging 2009, 53:9-19.
7. Kapoor V., McCook B.M., Torok F.S. An introduction to PET-CT imaging. Radiographics 2004, 24:523-543.
8. Reinhardt M., Beu M., Vosberg H., et al. Quantification of glucose transport and phosphorylation in human skeletal muscle using FDG PET. J Nucl Med 1999, 40:977-985.
9. Lindholm H., Johansson O., Jonsson C., et al. The distribution of FDG at PET examinations constitutes a relative mechanism: significant effects at activity quantification in patients with a high muscular uptake. Eur J Nucl Med Mol Imaging 2012, 39:1685-1690.
10. Minn H., Nuutila P., Lindholm P., et al. In vivo effects of insulin on tumor and skeletal muscle glucose metabolism in patients with lymphoma. Cancer 1994, 73:1490-1498.
11. Hara T., Higashi T., Nakamoto Y., et al. Significance of chronic marked hyperglycemia on FDG-PET: is it really problematic for clinical oncologic imagingα. Ann Nucl Med 2009, 23:657-669.
12. Herholz K., Langen K.J., Schiepers C., et al. Brain tumors. Semin Nucl Med 2012, 42:356-370.
13. Willmann O., Wennberg R., May T., et al. The contribution of 18F-FDG PET in preoperative epilepsy surgery evaluation for patients with temporal lobe epilepsy: A meta-analysis. Seizure 2007, 16:509-520.
14. Bloudek L.M., Spackman E., Blankenburg M., et al. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease. J Alzheimers Dis 2011, 26:627-645.
15. Moghbel M.C., Saboury B., Basu S., et al. Amyloid-β imaging with PET in Alzheimer's disease: is it feasible with current radiotracers and technologiesα. Eur J Nucl Med Mol Imaging 2012, 39:202-208.
16. Kepe V., Moghbel M.C., Långström B., et al. Amyloid-β positron emission tomography imaging probes: a critical review. J Alzheimers Dis 2013 May 6, [Epub ahead of print].
17. Zhang S., Han D., Tan X., et al. Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment. Int J Clin Pract 2012, 66:185-198.
18. Brooks D.J. Parkinson's disease: diagnosis. Parkinsonism Relat Disord 2012, 18(suppl 1):31-33.
19. Newberg A.B., Moss A.S., Monti D.A., et al. Positron emission tomography in psychiatric disorders. Ann N Y Acad Sci 2011, 1228:13-25.
20. Som P., Atkins H.L., Bandoypadhyay D., et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med 1980, 21:670-675.
21. Yonekura Y., Benua R.S., Brill A.B., et al. Increased accumulation of 2-deoxy-2-[18F]Fluoro-D-glucose in liver metastases from colon carcinoma. J Nucl Med 1982, 23:1133-1137.
22. Alavi J.B., Alavi A., Goldberg H.I., et al. Sequential computerized tomography and positron emission tomography studies in a patient with malignant glioma. Nucl Med Commun 1987, 8:457-468.
23. DiChiro G., Brooks R.A., Sokoloff L., et al. Glycolytic rate and histologic grade of human cerebral gliomas: A study with [18F]fluorodeoxyglucose and positron emission tomography. Positron Emission Tomography of the Brain 1983, 181-191.
24. Gambhir S.S., Czernin J., Schwimmer J., et al. A tabulated summary of the FDG PET literature. J Nucl Med 2001, 42(5 Suppl):1S-93S.
25. Facey K., Bradbury I., Laking G., et al. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess 2007, 11. iii-iv, xi-267.
26. Czernin J., Allen-Auerbach M., Schelbert H.R. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med 2007, 48(Suppl 1):78S-88S.
27. Bockisch A., Freudenberg L.S., Schmidt D., et al. Hybrid imaging by SPECT/CT and PET/CT: proven outcomes in cancer imaging. Semin Nucl Med 2009, 39:276-289.
28. Histed S.N., Lindenberg M.L., Mena E., et al. Review of functional anatomical imaging in oncology. Nucl Med Comm 2012, 33:349-361.
29. Basu S., Alavi A. Unparalleled contribution of 18F-FDG PET to medicine over 3 decades. J Nucl Med 2008, 49. 17N-21N,3N.
30. Basu S. The scope and potentials of functional radionuclide imaging towards advancing personalized medicine in oncology: Emphasis on PET-CT. Discov Med 2012, 13:65-73.
31. Høilund-Carlsen P.F., Gerke O., Vilstrup M.H., et al. PET/CT without capacity limitations: a Danish experience from a European perspective. Eur Radiol 2011, 21:1277-1285.
32. Pavlidis N., Fizazi K. Carcinoma of unknown origin (CUP). Crit Rev Oncol Hematol 2009, 69:271-278.
33. Kwee T.C., Kwee R.M. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol 2009, 19:731-744.
34. Linke R., Schroeder M., Helmberger T., et al. Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology 2004, 63:282-286.
35. Schramm N., Rominger A., Schmidt C., et al. Detection of underlying malignancy in patients with paraneoplastic neurological syndromes: comparison of (18)F-FDG PET/CT and contrast-enhanced CT. Eur J Nucl Med Mol Imaging 2013, 40:1014-1024.
36. Basu S., Alavi A. Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: Detection of the underlying malignancy and the brain PET-MRI correlates. Mol Imaging Biol 2008, 10:131-137.
37. Bannas P., Weber C., Derlin T., et al. 18F-FDG-PET/CT in the diagnosis of paraneoplastic neurological syndromes: a retrospective analysis. Eur Radiol 2010, 20:923-930.
38. Vaidyanathan S., Pennington C., Ng C.Y., et al. 18F-FDG-PET-CT in the evaluation of paraneoplastic syndromes: experience at a regional oncology centre. Nucl Med Commun 2012, 33:872-880.
39. Selva-O'Callaghan A., Grau J.M., Gámez-Cenzano C., et al. Conventional cancer screening versus PET/CT in dermatomyositis/polymyositis. Am J Med 2010, 123:558-562.
40. Kyle R.A., Rajkumar S.V. Multiple myeloma. Blood 2008, 111:2962-2972.
41. Hanrahan C.J., Christensen C.R., Crim J.R. Current concepts in the evaluation of multiple myeloma with MR imaging and FDG PET/CT. Radiographics 2010, 30:127-142.
42. Zamagni E., Cavo M. The role of imaging techniques in the management of multiple myeloma. Br J Haematol 2012, 159(5):499-513.
43. Lütje S., de Rooy J.W.J., Croockewit S., et al. Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma. Ann Hematol 2009, 88:1161-1168.
44. Shie P., Cardarelli R., Sprawls K., et al. Systematic review: prevalence of malignant incidental thyroid nodules identified on fluorine-18 fluorodeoxyglucose positron emission tomography. Nucl Med Commun 2009, 30:742-748.
45. Chae E.Y., Cha J.H., Kim H.H., et al. Analysis of incidental focal hypermetabolic uptake in the breast as detected by 18F-FDG PET/CT: clinical significance and differential diagnosis. Acta Radiol 2012, 53:530-535.
46. Treglia G., Calcagni M.L., Rufini V., et al. Clinical significance of incidental focal colorectal 18F-fluorodeoxyglucose uptake: our experience and a review of the literature. Colorectal Dis 2011, 14:174-180.
47. Beatty J.S., Williams H.T., Aldridge B.A., et al. Incidental PET/CT findings in the cancer patient: how should they be managedα. Surgery 2009, 146:274-281.
48. Kwee T.C., Basu S., Saboury B., et al. A new dimension of FDG-PET interpretation: assessment of tumor biology. Eur J Nucl Med Mol Imaging 2011, 38:1158-1170.
49. Hofman M.S., Hicks R. Changing paradigms with molecular imaging of neuroendocrine tumors. Discov Med 2012, 14:71-81.
50. Vach W., Høilund-Carlsen P.F., Gerke O., et al. Generating evidence for clinical benefit of PET/CT in diagnosing cancer patients. J Nucl Med 2011, 52(Suppl 2):77S-85S.
51. Tawakol A., Fayad Z.A., Mogg R., et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: Results of a multi-center FDG-PET/CT feasibility study. J Am Coll Cardiol 2013.
52. Tahara N., Kai H., Ishibashi M., et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006, 48:1825-1831.
53. Rudd J.H., Warburton E.A., Fryer T.D., et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 2002, 105:2708-2711.
54. Folco E.J., Sheikine Y., Rocha V.Z., et al. Hypoxia but not inflammation augments glucose uptake in human macrophages: Implications for imaging atherosclerosis with 18fluorine-labeled 2-deoxy-D-glucose positron emission tomography. J Am Coll Cardiol 2011, 58:603-614.
55. Tawakol A., Migrino R.Q., Bashian G.G., et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 2006, 48:1818-1824.
56. Marnane M., Merwick A., Sheehan O.C., et al. Carotid plaque inflammation on 18F-fluorodeoxyglucose positron emission tomography predicts early stroke recurrence. Ann Neurol 2012, 71:709-718.
57. Yun M., Jang S., Cucchiara A., et al. 18F FDG uptake in the large arteries: a correlation study with the atherogenic risk factors. Semin Nucl Med 2002, 32:70-76.
58. Bucerius J., Mani V., Moncrieff C., et al. Impact of noninsulin-dependent type 2 diabetes on carotid wall 18F-fluorodeoxyglucose positron emission tomography uptake. J Am Coll Cardiol 2012, 59:2080-2088.
59. Yun M., Yeh D., Araujo L.I., et al. F-18 FDG uptake in the large arteries: a new observation. Clin Nucl Med 2001, 26:314-319.
60. Tatsumi M., Cohade C., Nakamoto Y., et al. Fluorodeoxyglucose uptake in the aortic wall at PET/CT: possible finding for active atherosclerosis. Radiology 2003, 229:831-837.
61. Bucerius J., Duivenvoorden R., Mani V., et al. Prevalence and risk factors of carotid vessel wall inflammation in coronary artery disease patients: FDG-PET and CT imaging study. JACC Cardiovasc Imaging 2011, 4:1195-1205.
62. Kim T.N., Kim S., Yang S.J., et al. Vascular inflammation in patients with impaired glucose tolerance and type 2 diabetes: analysis with 18F-fluorodeoxyglucose positron emission tomography. Circ Cardiovasc Imaging 2010, 3:142-148.
63. Tahara N., Kai H., Yamagishi S., et al. Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol 2007, 49:1533-1539.
64. Davies J.R., Rudd J.H., Fryer T.D., et al. Identification of culprit lesions after transient ischemic attack by combined 18F fluorodeoxyglucose positron-emission tomography and high-resolution magnetic resonance imaging. Stroke 2005, 36:2642-2647.
65. Paulmier B., Duet M., Khayat R., et al. Arterial wall uptake of fluorodeoxyglucose on PET imaging in stable cancer disease patients indicates higher risk for cardiovascular events. J Nucl Cardiol 2008, 15:209-217.
66. Rominger A., Saam T., Wolpers S., et al. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med 2009, 50:1611-1620.
67. Tahara N., Kai H., Ishibashi M., et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006, 48:1825-1831.
68. Ishii H., Nishio M., Takahashi H., et al. Comparison of atorvastatin 5 and 20 mg/d for reducing F-18 fluorodeoxyglucose uptake in atherosclerotic plaques on positron emission tomography/computed tomography: a randomized, investigator-blinded, open-label, 6-month study in Japanese adults scheduled for percutaneous coronary intervention. Clin Ther 2010, 32:2337-2347.
69. Lee S.J., On Y.K., Lee E.J., et al. Reversal of vascular 18F-FDG uptake with plasma high-density lipoprotein elevation by atherogenic risk reduction. J Nucl Med 2008, 49:1277-1282.
70. Duivenvoorden R., Fayad Z.A. Utility of atherosclerosis imaging in the evaluation of high-density lipoprotein-raising therapies. Curr Atheroscler Rep 2011, 13:277-284.
71. Font M.A., Fernandez A., Carvajal A., et al. Imaging of early inflammation in low-to-moderate carotid stenosis by 18-FDG-PET. Front Biosci 2009, 14:3352-3360.
72. Rudd J.H., Myers K.S., Bansilal S., et al. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med 2008, 49:871-878.
73. Rudd J.H., Myers K.S., Bansilal S., et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol 2007, 50:892-896.
74. Camici P.G., Prasad S.K., Rimoldi O.E. Stunning, hibernation, and assessment of myocardial viability. Circulation 2008, 117:103-114.
75. Tillisch J., Brunken R., Marshall R., et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986, 314:884-888.
76. Auerbach M.A., Schoder H., Hoh C., et al. Prevalence of myocardial viability as detected by positron emission tomography in patients with ischemic cardiomyopathy. Circulation 1999, 99:2921-2926.
77. Schinkel A.F., Bax J.J., Poldermans D., et al. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol 2007, 32(7):375-410.
78. Schinkel A.F., Bax J.J., Delgado V., et al. Clinical relevance of hibernating myocardium in ischemic left ventricular dysfunction. Am J Med 2010, 123:978-986.
79. Gaemperli O., Kaufmann P.A. PET and PET/CT in cardiovascular disease. Ann N Y Acad Sci 2011, 1228:109-136.
80. Basu S., Zhuang H., Torigian D.A., et al. Functional imaging of inflammatory diseases using nuclear medicine techniques. Semin Nucl Med 2009, 39:124-145.
81. Basu S., Chryssikos T., Moghadam-Kia S., et al. Positron emission tomography as a diagnostic tool in infection: present role and future possibilities. Semin Nucl Med 2009, 39:36-51.
82. Zhuang H., Yu J.Q., Alavi A. Applications of fluorodeoxyglucose-PET imaging in the detection of infection and inflammation and other benign disorders. Radiol Clin North Am 2005, 43:121-134.
83. Kumar R., Basu S., Torigian D., et al. Role of modern imaging techniques for diagnosis of infection in the era of 18F-fluorodeoxyglucose positron emission tomography. Clin Microbiol Rev 2008, 21:209-224.
84. Basu S., Chryssikos T., Moghadam-Kia S., et al. Positron emission tomography as a diagnostic tool in infection: present role and future possibilities. Semin Nucl Med 2009, 39:36-51.
85. Tahara T., Ichiya Y., Kuwabara Y., et al. High [18F]-fluorodeoxyglucose uptake in abdominal abscesses: a PET study. J Comput Assist Tomogr 1989, 13:829-831.
86. Knockaert D.C., Vanderschueren S., Blockmans D. Fever of unknown origin in adults: 40 years on. J Intern Med 2003, 253:263-275.
87. Israel O., Keidar Z. PET/CT imaging in infectious conditions. Ann N Y Acad Sci 2011, 1228:150-166.
88. Kluge S., Braune S., Nierhaus A., et al. Diagnostic value of positron emission tomography combined with computed tomography for evaluating patients with septic shock of unknown origin. J Critical Care 2012, 27:316.e1-316.e7.
89. Bleeker-Rovers C.P., Vos F.J., Wanten G.J.A., et al. 18F-FDG PET in detecting metastatic infectious disease. J Nucl Med 2005, 46:2014-2019.
90. Hess S., Vind S.H., Skarphédinsson S., et al. Clinical value of PET/CT in bacteraemia of unknown origin. Results from an observational pilot study. Eur J Nucl Med Mol Imaging 2010, 37(suppl 2):S468.
91. Vos F.J., Bleeker-Rovers C.P., Sturm P.D., et al. 18F-FDG PET/CT for detection of metastatic infection in gram-positive bacteremia. J Nucl Med 2010, 51:1234-1240.
92. Vos F.J., Bleeker-Rovers C.P., Kullberg B.J., et al. Cost-effectiveness of routine (18)F-FDG PET/CT in high-risk patients with gram-positive bacteremia. J Nucl Med 2011, 52:1673-1678.
93. Millar B.C., Prendergast B.D., Alavi A., et al. (18)FDG-positron emission tomography (PET) has a role to play in the diagnosis and therapy of infective endocarditis and cardiac device infection. Int J Cardiol 2013 Jan 10, doi:pii: S0167-5273(12)01633-6. 10.1016/j.ijcard.2012.12.005. [Epub ahead of print].
94. Alavi A., Saboury B., Basu S. Imaging the infected heart. Sci Transl Med 2011, 3. 99fs3.
95. Guy S.D., Tramontana A.R., Worth L.J., et al. Use of FDG PET/CT for investigation of febrile neutropenia: evaluation in high-risk cancer patients. Eur J Nucl Med Mol Imaging 2012, 39:1348-1355.
96. Vos F.J., Donnelly J.P., Oyen W.J.G., et al. 18-F-FDG PET/CT for diagnosing infectious complications in patients with severe neutropenia after intensive chemotherapy for haematological malignancy or stem cell transplantation. Eur J Nucl Med Mol Imaging 2012, 39:120-128.
97. O'Doherty M.J., Barrington S.F., Campbell M., et al. PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med 1997, 38:1575-1583.
98. Castaigne C., Tondeur M., de Wit S., et al. Clinical value of FDG PET/CT for the diagnosis of human immunodeficiency virus-associated fever of unknown origin: a retrospective study. Nucl Med Commun 2009, 30:41-47.
99. Termaat M.F., Raijmakers P.G., Scholten H.J., et al. The accuracy of diagnostic imaging for the assessment of chronic osteomyelitis: a systematic review and meta-analysis. J Bone Joint Surg Am 2005, 87:2464-2471.
100. Schmitz A., Risse J.H., Grünwald F., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography findings in spondylodiscitis: preliminary results. Eur Spine J 2001, 10:534-539.
101. Stumpe K.D., Zanetti M., Weishaupt D., et al. FDG positron emission tomography for differentiation of degenerative and infectious endplate abnormalities in the lumbar spine detected on MR imaging. AJR Am J Roentgenol 2002, 179:1151-1157.
102. De Winter F., Gemmel F., Van De Wiele C., et al. 18-Fluorine fluorodeoxyglucose positron emission tomography for the diagnosis of infection in the postoperative spine. Spine (Phila Pa 1976) 2003, 28:1314-1319.
103. Schiesser M., Stumpe K.D., Trentz O., et al. Detection of metallic implant-associated infections with FDG PET in patients with trauma: correlation with microbiologic results. Radiology 2003, 226:391-398.
104. Hartmann A., Eid K., Dora C., et al. Diagnostic value of 18F-FDG PET/CT in trauma patients with suspected chronic osteomyelitis. Eur J Nucl Med Mol Imaging 2007, 34:704-714.
105. Kwee T.C., Kwee R.M., Alavi A. FDG-PET for diagnosing prosthetic joint infection: systematic review and metaanalysis. Eur J Nucl Med Mol Imaging 2008, 35:2122-2132.
106. Kwee T.C., Basu S., Torigian D.A., et al. FDG PET imaging for diagnosing prosthetic joint infection: discussing the facts, rectifying the unsupported claims and call for evidence-based and scientific approach. Eur J Nucl Med Mol Imaging 2013, 40:464-466.
107. Nawaz A., Torigian D.A., Siegelman E.S., et al. Diagnostic performance of FDG-PET, MRI, and plain film radiography (PFR) for the diagnosis of osteomyelitis in the diabetic foot. Mol Imaging Biol 2010, 12:335-342.
108. Basu S., Chryssikos T., Houseni M., et al. Potential role of FDG PET in the setting of diabetic neuro-osteoarthropathy: can it differentiate uncomplicated Charcot's neuroarthropathy from osteomyelitis and soft-tissue infectionα. Nucl Med Commun 2007, 28:465-472.
109. Kagna O., Srour S., Melamed E., et al. FDG PET/CT imaging in the diagnosis of osteomyelitis in the diabetic foot. Eur J Nucl Med Mol Imaging 2012, 39:1545-1550.
110. Legout L., D'Elia P.V., Sarraz-Bourmet B., et al. Diagnosis and management of prosthetic vascular graft infections. Med Mal Infect 2012, 42:102-109.
111. Basu S., Alavi A. Emerging role of FDG-PET for optimal response assessment in infectious diseases and disorders. Expert Rev Anti Infect Ther 2011, 9:143-145.
112. Nanni C., Boriani L., Salvadori C., et al. FDG PET/CT is useful for the interim evaluation of response to therapy in patients affected by haematogenous spondylodiscitis. Eur J Nucl Med Mol Imaging 2012, 39:1538-1544.
113. Zerizer I., Tan K., Khan S., et al. Role of FDG-PET and PET/CT in the diagnosis and management of vasculitis. Eur J Radiol 2010, 73:504-509.
114. Yamashita H., Kubota K., Takahashi Y., et al. Whole-body fluorodeoxyglucose positron emission tomography/computed tomography in patients with active polymyalgia rheumatica: evidence for distinctive bursitis and large-vessel vasculitis. Mod Rheumatol 2012, 22:705-711.
115. Basu S., Zhuang H., Torigian D.A., et al. Functional imaging of inflammatory diseases using nuclear medicine techniques. Sem Nucl Med 2009, 39:124-145.
116. Alavi A., Buchpiquel C.A., Loessner A. Is there a role for FDG PET imaging in the management of patients with sarcoidosisα. J Nucl Med 1994, 35:1650-1652.
117. Kwee T.C., Torigian D.A., Alavi A. Nononcological applications of positron emission tomography for evaluation of the thorax. J Thorac Imaging 2013, 28:25-39.
118. Israel-Biet D., Valeyre D. Diagnosis of pulmonary sarcoidosis. Curr Opin Pulm Med 2013 Jul 22, [Epub ahead of print].
119. Treglia G., Taralli S., Giordano A. Emerging role of whole-body 18F-fluorodeoxyglucose positron emission tomography as a marker of disease activity in patients with sarcoidosis: a systematic review. Sarcoidosis Vasc Diffuse Lung Dis 2011, 28:87-94.
120. Treglia G., Quartuccio N., Sadeghi R., et al. Diagnostic performance of Fluorine-18-Fluorodeoxyglucose positron emission tomography in patients with chronic inflammatory bowel disease: a systematic review and a meta-analysis. J Crohns Colitis 2013, 7:345-354.
121. Holtmann M.H., Uenzen M., Helisch A., et al. (18)F-fluorodeoxyglucose positron-emission tomography (PET) can be used to assess inflammation non-invasively in Crohn's disease. Dig Dis Sci 2012, 57:2658-2668.
122. Ahmadi A., Li Q., Muller K., et al. Diagnostic value of noninvasive combined fluorine-18 labeled fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography enterography in active Crohn's disease. Inflamm Bowel Dis 2010, 16:974-981.
123. Däbritz J., Jasper N., Loeffler M., et al. Noninvasive assessment of pediatric inflammatory bowel disease with 18F-fluorodeoxyglucose-positron emission tomography and computed tomography. Eur J Gastroenterol Hepatol 2011, 23:81-89.
124. Lenze F., Wessling J., Bremer J., et al. Detection and differentiation of inflammatory versus fibromatous Crohn's disease strictures: prospective comparison of (18) F-FDG-PET/CT, MR-enteroclysis, and transabdominal ultrasound versus endoscopic/histologic evaluation. Inflamm Bowel Dis 2012, 18:2252-2260.
125. Carey K., Saboury B., Basu S., et al. Evolving role of FDG PET imaging in assessing joint disorders: a systematic review. Eur J Nucl Med Mol Imaging 2011, 38:1939-1955.
126. dos Anjos D.A., do Vale G.F., Campos C de M., et al. Extra-articular inflammatory sites detected by F-18 FDG PET/CT in a patient with rheumatoid arthritis. Clin Nucl Med 2010, 35:540-541.
127. Strobel K., von Hochstetter A.R., Exner U.G. FDG uptake in a rheumatoid nodule with imaging appearance similar to a malignant soft tissue tumor. Clin Nucl Med 2009, 34:691-692.
128. Mountz J.M., Alavi A., Mountz J.D. Emerging optical and nuclear medicine imaging methods in rheumatoid arthritis. Nat Rev Rheumatol 2012, 8:719-728.
129. Kubota K., Ito K., Morooka M., et al. FDG PET for rheumatoid arthritis: basic considerations and whole-body PET/CT. Ann N Y Acad Sci 2011, 1228:29-38.
130. Sarma M., Vijayant V., Basu S. (18)F-FDG-PET assessment of early treatment response of articular and extra-articular foci in newly diagnosed rheumatoid arthritis. Hell J Nucl Med 2012, 15:70-71.
131. Elzinga E.H., van der Laken C.J., Comans E.F., et al. 18F-FDG PET as a tool to predict the clinical outcome of infliximab treatment of rheumatoid arthritis: an explorative study. J Nucl Med 2011, 52:77-80.
132. Aliyev A., Saboury B., Kwee T.C., et al. Age-related inflammatory changes in the spine as demonstrated by (18)F-FDG-PET: observation and insight into degenerative spinal changes. Hell J Nucl Med 2012, 15:197-201.
133. Lotz J.C., Haughton V., Boden S.D., et al. New treatments and imaging strategies in degenerative disease of the intervertebral disks. Radiology 2012, 264:6-19.
134. Mehta N.N., Yu Y., Saboury B., et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol 2011, 147:1031-1039.
135. Yu Y., Sheth N., Krishnamoorthy P., et al. Aortic vascular inflammation in psoriasis is associated with HDL particle size and concentration: a pilot study. Am J Cardiovasc Dis 2012, 2:285-292.
136. Hess S., Madsen P.H., Basu S., et al. FDG PET/CT in venous thromboembolic disease. Clin Nucl Med 2012, 37:1170-1172.
137. Rondina M.T., Lam U.T., Pendleton R.C., et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of acuity of deep vein thrombosis. Clin Nucl Med 2012, 37:1139-1145.
138. Adams M.C., Turkington T.G., Wilson J.M., et al. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol 2010, 195:310-320.
139. Boellaard R., O'Doherty M.J., Weber W.A., et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010, 37:181-200.
140. Wahl R.L., Jacene H., Kasamon Y., et al. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009, 50(suppl 1):122s-150s.
141. Soret M., Bacharach S.L., Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med 2007, 48:932-945.
142. Chawluk J.B., Alavi A., Dann R., et al. Positron emission tomography in aging and dementia: effect of cerebral atrophy. J Nucl Med 1987, 28:431-437.
143. Soret M., Bacharach S.L., Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med 2007, 48:932-945.
144. Cheng G., Torigian D.A., Zhuang H., et al. When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PETα. Eur J Nucl Med Mol Imaging 2013, 40:779-787.
145. Schillaci O. Use of dual-point fluorodeoxyglucose imaging to enhance sensitivity and specificity. Semin Nucl Med 2012, 42:267-280.
146. Hamberg L.M., Hunter G.J., Alpert N.M., et al. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplificationα. J Nucl Med 1994, 35:1308-1312.
147. Lodge M., Lucas J., Marsden P., et al. A PET study of (18)FDG uptake in soft tissue masses. Eur J Nucl Med 1999, 26:22-30.
148. Zhuang H., Pourdehnad M., Lambright E.S., et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001, 42:1412-1417.
149. Kumar R., Loving V.A., Chauhan A., et al. Potential of dual-time-point imaging to improve breast cancer diagnosis with 18F-FDG PET. J Nucl Med 2005, 46:1819-1824.
150. Matthies A., Hickeson M., Cuchiara A., et al. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 2002, 43:871-875.
151. Hustinx R., Smith R.J., Benard F., et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med 1999, 26:1345-1348.
152. Lee J.W., Kim S.K., Lee S.M., et al. Detection of hepatic metastases using dual-time-point FDG PET/CT scans in patients with colorectal cancer. Mol Imaging Biol 2011, 13:565-572.
153. Costantini D.L., Vali R., Chan J., et al. Dual-time-point FDG PET/CT for the evaluation of pediatric tumors. AJR Am J Roentgenol 2013, 200:408-413.
154. Berkowitz A., Basu S., Srinivas S., et al. Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET. Nucl Med Commun 2008, 29:521-526.
155. Van de Wiele C., Kruse V., Smeets P., et al. Predictive and prognostic value of metabolic tumour volume and total glycolysis in solid tumours. Eur J Nucl Med Mol Imaging 2013, 40:290-301.
156. Torigian D.A., Zaidi H., Kwee T.C., et al. PET/MR imaging: technical aspects and potential clinical applications. Radiology 2013, 267(1):26-44.
157. Mavi A., Urhan M., Yu J.Q., et al. Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med 2006, 47:1440-1446.